T
Tennor Therapeutics
Biotech & Life Sciences · Suzhou Shi, China · Founded 2013
Specializes in research and development of new drugs for the treatment of digestive diseases MoreLess
TenNor Therapeutics is a biotechnology company specializing in the development of innovative antibiotic treatments for complex infections. The company primarily serves healthcare providers and medical institutions, focusing on addressing unmet medical needs in the treatment of anaerobic pathogens and periprosthetic joint infections. Operating in the global pharmaceutical market, TenNor leverages advanced research and development to create novel antibiotic conjugates, such as oxazolidinone nitroimidazole, which have shown synergistic activity against difficult-to-treat infections. The business model revolves around the development and commercialization of these specialized antibiotics, generating revenue through product sales, licensing agreements, and collaborations with other pharmaceutical companies. TenNor's strategic partnerships with renowned institutions like the Mayo Clinic further bolster its research capabilities and market reach.
Keywords: biotechnology, antibiotics, anaerobic pathogens, joint infections, pharmaceutical, research, development, healthcare, innovation, partnerships.
Company overview
Tennor Therapeutics company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2013
- Headquarters
- Suzhou Shi, China
- Employees
- 6
- Open positions
- None listed
- Dealroom signal
- 59.8
Valuation & funding
Tennor Therapeutics funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| IPOOther financing | May 2026 | $67M | — | Undisclosed | ↗ |
| SERIES EOther financing | Oct 2024 | $42M | $169M | AMR Action Fund · Zhongshan Venture Capital | ↗ |
| SERIES DOther financing | Dec 2022 | $9.5M | $125M | Broad Resources · Yanchuang Capital · Beijing Venture Capital | ↗ |
| SERIES DOther financing | Mar 2022 | $36M | $145M | Bison Capital Financial Holdings · ShenZhen GTJA Investment Group · Galaxy Capital · Yanchuang Capital | ↗ |
| SERIES BOther financing | Sep 2016 | $25M | $100M | Relativity Healthcare Partners · WuXi Healthcare Ventures · NLVC · Frontline BioVentures | — |
| GRANTOther financing | Feb 2016 | Undisclosed | — |
Financials
Revenue and workforce over time
Available revenue and workforce history. Fields without reported data are omitted.
| Year | Revenue | Growth | Employees |
|---|---|---|---|
| 2026 | $679K | 0% | 6 |
| 2025 | $679K | 0% | — |
| 2024 | $679K | +9.3% | — |
| 2023 | $621K | — | — |
Growth signals
Tennor Therapeutics website traffic
Latest recorded traffic for Tennor Therapeutics is 150 monthly website visits, down 92.1% over the last three months.
Comparisons
Tennor Therapeutics compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Tennor Therapeutics's talent
Source: Dealroom Talent Intelligence.
Investors
16 investors on Tennor Therapeutics's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Tennor Therapeutics has talent and traffic
team presence
In the news
Latest news about Tennor Therapeutics
Recent press, funding announcements, and product moves mentioning Tennor Therapeutics — open to read from the original sources.
Market sentiment
What the market is saying about Tennor Therapeutics
An AI-synthesized read of the highest-engagement posts about Tennor Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Tennor Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.